Related Experiment Video
Updated: Aug 7, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
First line chemotherapy in advanced or metastatic NSCLC
M Rinaldi1, C Cauchi, C Gridelli
1U.O. Oncologia Medica B, Istituto Tumori Regina Elena, Roma, Italy. mas_rinaldi@yahoo.it
Summary
Gemcitabine-platinum combinations significantly improve survival outcomes for Non-Small Cell Lung Cancer (NSCLC) patients compared to other platinum regimens. This finding supports two-drug chemotherapy for advanced NSCLC, with pharmacogenomics offering future personalized treatment potential.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Global lung cancer incidence is rising, with Non-Small Cell Lung Cancer (NSCLC) comprising 80% of cases.
- Current platinum-based chemotherapy regimens offer limited survival benefits for advanced NSCLC.
- Research has explored various drug combinations, but a definitive standard regimen remains elusive.
Purpose of the Study:
- To evaluate the efficacy of gemcitabine-platinum combinations versus other platinum-based regimens in advanced NSCLC.
- To assess overall survival (OS) and progression-free survival (PFS) outcomes.
- To inform first-line chemotherapy recommendations for advanced NSCLC.
Main Methods:
- Meta-analysis of published randomized trials.
- Comparison of gemcitabine-platinum combinations against alternative platinum-based regimens.
- Analysis of survival outcomes, including OS and PFS.
Main Results:
- Gemcitabine-platinum combinations demonstrated statistically significant superior efficacy in both overall survival and progression-free survival.
- The meta-analysis supports the use of two-drug combination regimens for advanced NSCLC.
- Non-cisplatin-containing regimens may serve as alternatives to reduce toxicity.
Conclusions:
- Gemcitabine-platinum combinations represent an effective first-line treatment option for advanced NSCLC.
- Current evidence supports two-drug chemotherapy regimens over monotherapy.
- Pharmacogenomics holds promise for personalized NSCLC treatment by predicting response and minimizing side effects.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...